Redmile Group LLC trimmed its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 8.6% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 657,175 shares of the biopharmaceutical company's stock after selling 61,548 shares during the quarter. Celldex Therapeutics comprises about 1.3% of Redmile Group LLC's investment portfolio, making the stock its 28th largest holding. Redmile Group LLC owned approximately 0.99% of Celldex Therapeutics worth $22,337,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. Point72 DIFC Ltd raised its stake in shares of Celldex Therapeutics by 101.7% during the 3rd quarter. Point72 DIFC Ltd now owns 14,114 shares of the biopharmaceutical company's stock worth $480,000 after acquiring an additional 7,116 shares in the last quarter. Bellevue Group AG increased its position in shares of Celldex Therapeutics by 3.4% during the third quarter. Bellevue Group AG now owns 3,071,615 shares of the biopharmaceutical company's stock worth $104,404,000 after purchasing an additional 100,000 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Celldex Therapeutics by 6.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 102,595 shares of the biopharmaceutical company's stock valued at $3,487,000 after purchasing an additional 6,269 shares during the last quarter. BNP Paribas Financial Markets boosted its position in shares of Celldex Therapeutics by 293.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 28,181 shares of the biopharmaceutical company's stock worth $958,000 after purchasing an additional 21,013 shares in the last quarter. Finally, Fisher Asset Management LLC boosted its position in shares of Celldex Therapeutics by 210.6% in the 3rd quarter. Fisher Asset Management LLC now owns 374,352 shares of the biopharmaceutical company's stock worth $12,724,000 after purchasing an additional 253,808 shares in the last quarter.
Celldex Therapeutics Stock Performance
NASDAQ CLDX traded down $0.52 on Thursday, reaching $26.06. 583,543 shares of the company's stock traded hands, compared to its average volume of 881,321. Celldex Therapeutics, Inc. has a fifty-two week low of $22.93 and a fifty-two week high of $53.18. The firm has a market cap of $1.73 billion, a price-to-earnings ratio of -10.14 and a beta of 1.57. The stock has a 50 day moving average price of $27.93 and a 200-day moving average price of $34.10.
Insider Buying and Selling at Celldex Therapeutics
In related news, CEO Anthony S. Marucci acquired 11,500 shares of the stock in a transaction on Monday, November 11th. The shares were acquired at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the transaction, the chief executive officer now owns 40,284 shares in the company, valued at approximately $1,080,416.88. This trade represents a 39.95 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 3.80% of the company's stock.
Analyst Upgrades and Downgrades
CLDX has been the subject of a number of research analyst reports. Wells Fargo & Company upgraded Celldex Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Thursday, September 26th. HC Wainwright restated a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, November 20th. Wolfe Research cut shares of Celldex Therapeutics from an "outperform" rating to a "peer perform" rating in a research note on Friday, September 27th. The Goldman Sachs Group assumed coverage on shares of Celldex Therapeutics in a research report on Monday, September 30th. They set a "neutral" rating and a $45.00 target price on the stock. Finally, Citigroup assumed coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They issued a "buy" rating and a $70.00 price target for the company. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $62.25.
Get Our Latest Report on Celldex Therapeutics
Celldex Therapeutics Profile
(
Free Report)
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Read More
Before you consider Celldex Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.
While Celldex Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
